US biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and lung scarring in patients who have serious cases of COVID-19 or who have ...
The company aims to bring a more patient-friendly therapy for IPF to market based on a deuterated form of pirfenidone – called LYT-100 (deupirfenidone) – that it hopes will retain its efficacy ...
Hosted on MSN2mon
PureTech Health stock hits 52-week low at $16.81 amid market shiftsThis study evaluated the potential of their wholly-owned asset LYT-100 (deupirfenidone) for use in treating idiopathic pulmonary fibrosis (IPF). Analysts from Leerink Partners, who maintain an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback